A novel nitroreductase and therapeutic uses therefor
CA 2325050 A1 · Owner: Hoffman, Paul S. · Inventors: Goodwin, Avery; Hoffman, Paul S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In accordance with the present invention the gene responsible for , metronidazole sensitivity in H. pylori has been identified. Mutational inactivation of the gene, which encodes an oxygen-insensitive NADPH nitroreductase, referred to herein as rdxA (designated HP0954 in the entire genome sequence) (Tomb et al. 1997) is the cause of naturally acquired MtzR in H. pylori. In accordance with one embodiment of the present invention there is provided a method of employing RdxA and related compounds optionally , in conjunction with targeting compounds to convert nitroaromatic compounds to cytotoxins for use in selectively killing or inhibiting the growth of target cell populations. In …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 6, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 6, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 6, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.